Overview
BLCO market data
Price History
BLCO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.54 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.61 – $18.92 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6B · P/B 0.94 · P/S 1.13.
Company News
8-K/A filing — Bausch & Lomb Corp (BLCO)SEC EDGAR · Aug 12, 2026, 11:01 AM
8-K filing — Bausch & Lomb Corp (BLCO)SEC EDGAR · Aug 6, 2026, 11:10 AM
HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $21Benzinga · Aug 3, 2026, 10:37 AM
UBS Maintains Buy on Bausch & Lomb, Raises Price Target to $23Benzinga · Jul 30, 2026, 8:32 PM
Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B EstimateBenzinga · Jul 29, 2026, 11:00 AM
Bausch & Lomb Raises FY2026 Sales Guidance from $5.420B-$5.520B to $5.440B-$5.540B vs $5.468B EstBenzinga · Jul 29, 2026, 10:58 AM
UBS Initiates Coverage On Bausch & Lomb with Buy Rating, Announces Price Target of $21Benzinga · Jul 28, 2026, 6:39 PM
Bausch + Lomb Announces U.S. Launch Of EyeGility Inserter Preloaded IOL Delivery SystemBenzinga · Jul 16, 2026, 11:05 AM
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 OthersGlobenewswire Inc · Jul 13, 2026, 12:45 PM
Bausch + Lomb Ends Glaucoma Drug Development, Shifts FocusBenzinga · Jul 10, 2026, 2:25 PM